TYK MEDICINES-B (02410) rose more than 5%, with a gain of 4.92% at the time of writing to HK$11.34, generating a turnover of HK$27.5877 million. On March 4, the company announced that the conversion of 4.608 million non-listed shares into H-shares was completed on March 4, 2026. These converted H-shares are scheduled to commence trading on the Stock Exchange of Hong Kong at 9:00 a.m. on March 5, 2026. Recently, TYK MEDICINES-B announced that the new drug application for its self-developed TY-9591 mesylate tablets, targeting brain metastases in non-small cell lung cancer, has been formally accepted by the Center for Drug Evaluation of China's National Medical Products Administration. This marks the first next-generation EGFR-TKI inhibitor specifically for lung cancer brain metastases. The NDA submission is based on results from a key multicenter, randomized, open-label, active-controlled registrational clinical study conducted in China. The study's findings are expected to be presented at an upcoming international academic conference or published in a scientific journal.